Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial.

Diabet Med · 2010 · PMC3068287 · PMID 20722676

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

A clear trend of systolic and diastolic blood pressure reductions from baseline to end-point occurred with each lixisenatide dose (ranging from −2 to −9 mmHg for the systolic, and −2 to −4 mmHg for the diastolic blood pressures), and also with placebo (−3 and −2 mmHg for systolic and diastolic blood pressures, respectively).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.